'No compelling case for cuts': Wall Street's takeaways from Kevin Warsh's testimony

Kevin Warsh’s Fed chair hearing signaled no near-term case for rate cuts, with Bank of America saying his outlook is more consistent with an extended hold than additional easing. Warsh also indicated a preference for trimmed-mean and median inflation measures over core PCE, keeping inflation above the Fed’s 2% target and potentially increasing the policy weight of food and energy shocks. His path to confirmation remains uncertain, as Sen. Thom Tillis said he will oppose the nomination until the Powell criminal investigation is resolved, risking a tied committee vote and a 60-vote Senate threshold.

Analysis

The immediate market implication is not about rate cuts per se, but about the repricing of the policy path distribution. A Fed chair nominee who signals tolerance for tighter-for-longer conditions raises the odds of higher real yields at the front end, which is more damaging for duration-sensitive assets than a single cut delay. That is a subtle but important shift: the market should price less easing optionality, not necessarily a full hawkish regime change.

Financials are a relative beneficiary only if the move in yields is driven by a steeper curve rather than a pure front-end selloff. In a flat-to-inverted re-pricing, banks like BAC face a mixed setup: deposit beta pressure eases, but loan demand and capital markets activity can slow. GS is less rate-sensitive on earnings, but a tougher Fed narrative can still weigh on underwriting, M&A timing, and fee pools, especially if equity multiples compress.

IBKR is the cleaner expression because its economics benefit from volatility, higher rates on customer cash, and elevated trading engagement. The second-order effect is that a more hawkish nominee may actually extend the window of elevated rates/volatility long enough to support brokerage monetization even if equities wobble. The market may be underestimating how much a credibility-driven Fed can keep real rates restrictive even under political pressure.

The key contrarian risk is political and procedural, not macro: confirmation odds may deteriorate before policy even matters. If the committee process stalls or the Powell investigation becomes the gating item, the whole curve trade can unwind quickly as investors revert to a more dovish successor path. That makes this a two-step event: near-term headline risk around confirmation, followed by medium-term repricing of the Fed reaction function if Warsh advances.

Key Decisions for Investors

• Long IBKR vs short BAC into the confirmation window: IBKR should outperform if rates stay elevated and trading activity stays firm; BAC is more exposed to a flatter curve and slower loan growth. Target 4-8% relative upside over 4-6 weeks, with the thesis invalidated if the curve steepens meaningfully or confirmation odds collapse.
• Sell near-dated rate-cut sensitivity via options: buy puts on rate-sensitive REIT/utility proxies or short duration-heavy growth baskets for 30-60 days. This is a lower-conviction macro hedge against a repricing of fewer cuts, with asymmetric payoff if front-end yields back up 20-40 bps.
• Maintain a tactical long GS only on market volatility spikes, not as a rates proxy. Best entry is after any confirmation-related selloff in financials; reward improves if higher rates come with sustained capital markets activity, but downside is limited if the curve inversion deepens.
• Avoid chasing BAC on the headline; use it as a funding leg in pair trades rather than outright long. The stock benefits only if the market reads this as a steeper-curve story, which is not the base case. Risk/reward is poor versus IBKR over the next 1-2 months.
• Watch Senate process headlines as the real catalyst calendar. If the vote is delayed or the opposition broadens, fade any hawkish-rate trade quickly; if Warsh clears committee, extend the trade into the first FOMC reaction window over the next 1-3 months.